Amgen Reports Second Quarter 2016 Financial Results Read more about Amgen Reports Second Quarter 2016 Financial Results
Amgen Announces Webcast Of 2016 Second Quarter Financial Results Read more about Amgen Announces Webcast Of 2016 Second Quarter Financial Results
Amgen Announces 2016 Third Quarter Dividend Read more about Amgen Announces 2016 Third Quarter Dividend
Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA Read more about Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA
Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer Read more about Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
Amgen Announces Settlement Of Securities Litigation Read more about Amgen Announces Settlement Of Securities Litigation
Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan Read more about Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan
European Commission Approves Extended Indication For Amgen's Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients Read more about European Commission Approves Extended Indication For Amgen's Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients
Amgen To Discuss Data Supporting Biologics License Application For ABP 501, A Biosimilar Candidate To Adalimumab Read more about Amgen To Discuss Data Supporting Biologics License Application For ABP 501, A Biosimilar Candidate To Adalimumab
FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor Read more about FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor
